Comparison of efficacy and safety of 5-day and 10-day schedules of SGI-110, a novel subcutaneous (SC) hypomethylating agent (HMA), in the treatment of relapsed/refractory acute myeloid leukemia (r/r AML)

Trial Profile

Comparison of efficacy and safety of 5-day and 10-day schedules of SGI-110, a novel subcutaneous (SC) hypomethylating agent (HMA), in the treatment of relapsed/refractory acute myeloid leukemia (r/r AML)

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Dec 2016

At a glance

  • Drugs Guadecitabine (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Dec 2016 Results reporting long tem survival and composite complete response (CRc) rate data in various prognostic subgroups in the overall relapsed/refractory acute myeloid leukemia patient population treated with guadecitabine, presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 24 Sep 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top